| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | AZD0530 | FIMM | pan-cancer | AAC | -0.015 | 0.9 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |